AIM Investors

Issue of Equity and Total Voting Rights

By December 21, 2016No Comments

Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics announces that it has issued 467,024 new ordinary shares in the Company (“Ordinary Shares”) as a result of the exercise of warrants and options.

Application has been made for the 467,024 new Ordinary Shares to be admitted to trading on AIM (“Admission”), which is expected to occur at 8.00 a.m. on 28 December 2016. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. Following Admission, and for the purposes of the Disclosure and Transparency Rules, the Company’s total issued share capital will consist of 181,230,758 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

Company Contacts

Motif Bio plc

Graham Lumsden, Chief Executive Officer
info@motifbio.com

Zeus Capital Limited (Nominated Advisor and Broker)

Phil Walker / Giles Balleny
Dominic Wilson
+44 (0) 20 3829 5000

Northland Capital Partners Limited (Broker)

Patrick Claridge / David Hignell
John Howes / Rob Rees (Broking)
+44 (0) 207 382 1100

Walbrook PR Ltd. (Public and Investor Relations)

Paul McManus / Mike Wort
Main: +44 (0)20 7933 8780
Paul: +44 (0)7980 541 893
Mike: +44 (0)7900 608 002
motifbio@walbrookpr.com

MC Services AG (European IR)

Raimund Gabriel
+49 (0) 89 210 2280